Literature DB >> 14551864

Newly developed Barrett's esophagus after subtotal esophagectomy.

D Franchimont1, A Covas, C Brasseur, J-L Van Laethem, I El-Nakadi, J Devière.   

Abstract

BACKGROUND AND STUDY AIMS: More detailed information regarding the early mucosal events that lead to intestinal metaplasia would be very beneficial for understanding the pathogenesis of Barrett's esophagus (BE). Gastroesophageal reflux and duodenogastroesophageal reflux play a major role in the pathogenesis of Barrett's esophagus. The aim of this study was to investigate the prevalence of newly developed BE in patients who had previously undergone a subtotal esophagectomy - a clinical condition characterized by the absence of a lower esophageal sphincter and massive gastroesophageal reflux. PATIENTS AND METHODS: A retrospective examination was carried out on all patients who underwent subtotal esophagectomy (n = 87) listed in our institution's computer files from 1995 to 2000. Twenty-one patients were excluded due to missing data or no upper gastrointestinal endoscopy after surgery.
RESULTS: Based on the Savary-Miller classification, 47 patients developed either type I (n = 2), II (n = 8), III (n = 11) or IV (n = 26) esophagitis after surgery. Newly developed BE was observed in nine patients (13.5 %) after subtotal esophagectomy (median time to diagnosis: 489 days, range 43 - 1172). None of the patients had persistent BE immediately after surgery, and two of the patients with newly developed BE had had no history of BE before surgery or at the time of surgery. Proton-pump inhibitor therapy after surgery and neoadjuvant chemotherapy did not appear to influence the development of BE after subtotal esophagectomy.
CONCLUSIONS: Newly developed BE after subtotal esophagectomy may provide further insights into the early mucosal events that lead to intestinal metaplasia and into the roles of gastroesophageal and duodenoesophageal reflux in the pathogenesis of BE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551864     DOI: 10.1055/s-2003-42623

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  6 in total

Review 1.  Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how?

Authors:  Vani J A Konda; Mark K Ferguson
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

Review 2.  The role of acid and bile reflux in oesophagitis and Barrett's metaplasia.

Authors:  Rhonda F Souza
Journal:  Biochem Soc Trans       Date:  2010-04       Impact factor: 5.407

Review 3.  Endotherapy for Barrett's esophagus with high-grade dysplasia and intramucosal carcinoma.

Authors:  Drew B Schembre
Journal:  J Gastrointest Surg       Date:  2009-03-26       Impact factor: 3.452

Review 4.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

5.  Clinical analysis of reflux esophagitis following esophagectomy with gastric tube reconstruction.

Authors:  Soichiro Yamamoto; Hiroyasu Makuuchi; Hideo Shimada; Osamu Chino; Takayuki Nishi; Yoshifumi Kise; Takahiro Kenmochi; Tadashi Hara
Journal:  J Gastroenterol       Date:  2007-05-25       Impact factor: 7.527

6.  Squamous tissue lymphocytes in the esophagus of controls and patients with reflux esophagitis and Barrett's esophagus are characterized by a non-inflammatory phenotype.

Authors:  Alexandra Lind; Leo Koenderman; Johannes G Kusters; Peter D Siersema
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.